Emergent BioSolutions (NYSE:EBS) has been issued a task order,
valued at ~$628M, under an existing contract with the Biomedical
Advanced Research and Development Authority (BARDA), to deploy its
contract development and manufacturing (CDMO) capacities, capabilities,
and expertise to support the U.S. government’s efforts to accelerate
delivery of COVID-19 vaccines.
Emergent will deploy its molecule-to-market CDMO
offering, committing manufacturing capacity, valued at ~$542.7M, for
production of COVID-19 vaccine candidates through 2021.
Task order also includes an investment of ~$85.5M
for rapid expansion of Emergent’s viral and non-viral CDMO drug product
fill/finish capacity.
This task order also expands the partnership to
include investments in Emergent’s Baltimore Camden
and Rockville facilities to advance COVID-19 programs.
https://seekingalpha.com/news/3578929-emergent-bio-joins-warp-speed-covidminus-19-vaccine-effort
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.